Year: 2021

First subject dosed with Nykode Therapeutics’ T cell focused SARS-CoV-2 vaccine candidate. This is part of the ongoing phase 1/2 two-arm clinical trial VB-D-01 designed to specifically address emerging variants of concern, including Omicron1 The T cell focused vaccine candidate (VB10.2210) encodes 96 clinically validated T cell epitopes spanning a total of eight SARS-CoV-2 proteins, including Spike. These Spike- and non-Spike T cell epitopes have been identified and validated by Adaptive Biotechnologies using their immune medicine platform Initial analysis indicates that no epitopes outside the Spike are affected by the Omicron variantOSLO, Norway, Dec. 28, 2021 (GLOBE NEWSWIRE) — Nykode Therapeutics AS (Euronext Growth (Oslo): NYKD), a clinical-stage biopharmaceutical company dedicated to the discovery and development of vaccines...

CRIF – a global company specializing in credit bureau and business information, as well as advanced digital solutions for business development and open banking – announces the acquisition of ICAP – the largest B2B Services Group in Greece, with a strong presence also in Romania, Bulgaria and Cyprus. ICAP was established in 1964; in 2007 South Eastern Europe Fund, advised by Global Finance, acquired the majority stake with Coface, one of the world’s largest credit insurers and business information providers, and management participating in the acquisition. With 259 employees, ICAP currently serves local markets and global clients through a wide range of added value services and innovative solutions in the field of Credit Risk & Business Information Solutions. Moreover ICAP is the only company in Greece that has been...

GUANGZHOU, China, Dec. 27, 2021 (GLOBE NEWSWIRE) — Burning Rock Biotech Limited (NASDAQ: BNR, the “Company” or “Burning Rock”), a company focused on the application of next generation sequencing (NGS) technology in the field of precision oncology, today announced that all shareholder resolutions proposed at the Company’s 2021 annual general meeting held today were duly passed. Specifically, the shareholders passed the following resolutions approving:the ratification of the appointment of Ernst & Young Hua Ming LLP as auditor of the Company for the fiscal year ending December 31, 2021 and the authorization for the directors of the Company to determine the remuneration of the auditor; the re-election of Yusheng Han, Gang Lu and Shaokun Chuai as directors of the Company; the approval, confirmation and ratification of the adoption...

New York, NY, Dec. 27, 2021 (GLOBE NEWSWIRE) — Welsbach Technology Metals Acquisition Corp. (the “Company”) announced today that it priced its initial public offering of 7,500,000 units, at $10.00 per unit. The units will be listed on the Nasdaq Global Market (“Nasdaq”) and will begin trading tomorrow, Tuesday, December 28, 2021, under the ticker symbol “WTMAU.” Each unit consists of one share of the Company’s common stock and one right to receive one-tenth (1/10) of a share of common stock upon the consummation of an initial business combination. Once the securities comprising the units begin separate trading, the shares of common stock and rights are expected to be listed on Nasdaq under the symbols “WTMA” and “WTMAR,” respectively. The offering is expected to close on December 30, 2021, subject to customary closing conditions. The...

IRVINE, Calif., Dec. 27, 2021 (GLOBE NEWSWIRE) — Eledon Pharmaceuticals, Inc. (“Eledon”) (NASDAQ: ELDN), a patient-focused clinical stage biopharmaceutical company committed to the development of innovative and impactful treatments for organ and cell transplantation, autoimmune conditions, and neurodegenerative disease, today announced that members of management will be participating in two upcoming virtual investor conferences:Event: LifeSci Partners Corporate Access Event (January 5-7, 2022)Format: 1×1 Meetings   To register for the LifeSci Partners Corporate Access Event, please use the following link: here.Event: H.C. Wainwright BIOCNNECT Virtual Conference (January 10-13, 2022)Format: Available on Demand Presentation for registered attendees via the H.C. Wainwright site and 1×1 Meetings   If...

THE WOODLANDS, Texas, Dec. 27, 2021 (GLOBE NEWSWIRE) — The following is being released by Conn’s, Inc. pursuant to an Order of the United States District Court of the Southern District of Texas, Houston Division. This press release relates to the proposed settlement of litigation that was filed in 2014 and captioned:  Robert Hack, derivatively on behalf of Conn’s Inc. v. Theodore M. Wright, et al., Civil Action No. 4:14-CV-3442 (KPE); In the United States District Court of the Southern District of Texas, Houston Division SUMMARY NOTICE OF PROPOSED SETTLEMENT OF STOCKHOLDER DERIVATIVE ACTION The United States District Court for the Southern District of Texas authorized this Notice.This is not a solicitation from an attorney TO: ALL RECORD HOLDERS AND BENEFICIAL OWNERS OF CONN’S, INC. (“CONN’S”) COMMON STOCK (TICKER SYMBOL: CONN)...

Nasdaq Short Interest DaysNasdaq Short Interest DaysNEW YORK, Dec. 27, 2021 (GLOBE NEWSWIRE) — At the end of the settlement date of December 15, 2021, short interest in 3,103 Nasdaq Global MarketSM securities totaled 8,912,688,445 shares compared with 8,555,941,286 shares in 3,036 Global Market issues reported for the prior settlement date of November 30, 2021. The mid-December short interest represents 2.40 days compared with 2.46 days for the prior reporting period. Short interest in 2,107 securities on The Nasdaq Capital MarketSM totaled 2,337,458,762 shares at the end of the settlement date of December 15, 2021 compared with 2,263,829,860 shares in 2,118 securities for the previous reporting period. This represents a 1.58 day average daily volume; the previous reporting period’s figure was 1.29. In summary,...

HOLLYWOOD, FL, Dec. 27, 2021 (GLOBE NEWSWIRE) — Healthier Choices Management Corp. (“HCMC” or the “Company”) (OTC Pink: HCMC) today released a year-end letter from Jeffrey Holman, its CEO, to the Company’s shareholders. The letter follows below and can also be accessed from the Company’s website at www.HealthierCMC.com. December 27, 2021 Dear Valued Shareholders, As the end of a very tumultuous year closes, I wanted to take a moment to thank all of our valued shareholders and reiterate some of the things that we hope to accomplish in 2022. As always, one of our primary goals is to enhance shareholder value. We recognize that at year end many investors strategically sell shares of stocks to take year-end losses for tax purposes. This is an inevitable function of the market and our Company’s stock...

Infant Bacterial Therapeutics AB today announces that the Patent Offices of Brazil and Hong Kong have approved a patent of Lactobacillus reuteri covering IBP-9414. IBT is currently developing its drug candidate IBP-9414 in Phase III for the prevention of necrotizing colitis and improvement of feeding tolerance in preterm infants. The patent covers a novel way to activate the bacteria. Corresponding patent applications are currently pending across several important future markets. This patent reinforces the existing protection of IBT’s drug candidate IBP-9414. Additional market protection, beyond patent exclusivity, is also anticipated in the form of Orphan Drug Exclusivity and biological data protection in the US and EU. The patent provides coverage until 2036. IBP-9414 is intended to be marketed in Brazil and Hong Kong upon marketing...